These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 23084402)

  • 1. Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.
    Treon SP; Tripsas C; Hanzis C; Ioakimidis L; Patterson CJ; Manning RJ; Sheehy P; Turnbull B; Hunter ZR
    Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):433-7. PubMed ID: 23084402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia.
    Treon SP; Yang G; Hanzis C; Ioakimidis L; Verselis SJ; Fox EA; Xu L; Hunter ZR; Tseng H; Manning RJ; Patterson CJ; Sheehy P; Turnbull B
    Br J Haematol; 2011 Jul; 154(2):223-8. PubMed ID: 21564078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.
    Ghobrial IM; Xie W; Padmanabhan S; Badros A; Rourke M; Leduc R; Chuma S; Kunsman J; Warren D; Poon T; Harris B; Sam A; Anderson KC; Richardson PG; Treon SP; Weller E; Matous J
    Am J Hematol; 2010 Sep; 85(9):670-4. PubMed ID: 20652865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How I treat Waldenström macroglobulinemia.
    Treon SP
    Blood; 2015 Aug; 126(6):721-32. PubMed ID: 26002963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
    Dimopoulos MA; Anagnostopoulos A; Kyrtsonis MC; Castritis E; Bitsaktsis A; Pangalis GA
    Haematologica; 2005 Dec; 90(12):1655-8. PubMed ID: 16330439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia.
    Leleu X; Xie W; Bagshaw M; Banwait R; Leduc R; Roper N; Weller E; Ghobrial IM
    Clin Cancer Res; 2011 May; 17(9):3013-8. PubMed ID: 21415221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
    Treon SP; Ioakimidis L; Soumerai JD; Patterson CJ; Sheehy P; Nelson M; Willen M; Matous J; Mattern J; Diener JG; Keogh GP; Myers TJ; Boral A; Birner A; Esseltine DL; Ghobrial IM
    J Clin Oncol; 2009 Aug; 27(23):3830-5. PubMed ID: 19506160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.
    Ghobrial IM; Hong F; Padmanabhan S; Badros A; Rourke M; Leduc R; Chuma S; Kunsman J; Warren D; Harris B; Sam A; Anderson KC; Richardson PG; Treon SP; Weller E; Matous J
    J Clin Oncol; 2010 Mar; 28(8):1422-8. PubMed ID: 20142586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
    Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
    J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
    Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.
    Agathocleous A; Rohatiner A; Rule S; Hunter H; Kerr JP; Neeson SM; Matthews J; Strauss S; Montoto S; Johnson P; Radford J; Lister A
    Br J Haematol; 2010 Nov; 151(4):346-53. PubMed ID: 20880120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib in relapsed or refractory Waldenström's macroglobulinemia.
    Chen C; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):74-6. PubMed ID: 19362979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: results and cost analysis.
    Annibali O; Petrucci MT; Martini V; Tirindelli MC; Levi A; Fossati C; Del Bianco P; Mandelli F; Foa R; Avvisati G
    Cancer; 2005 Feb; 103(3):582-7. PubMed ID: 15611977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
    Dimopoulos MA; García-Sanz R; Gavriatopoulou M; Morel P; Kyrtsonis MC; Michalis E; Kartasis Z; Leleu X; Palladini G; Tedeschi A; Gika D; Merlini G; Kastritis E; Sonneveld P
    Blood; 2013 Nov; 122(19):3276-82. PubMed ID: 24004667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of Waldenström´s macroglobulinaemia in the year 2014].
    Adam Z; Krejčí M; Pour L; Ševčíková E
    Vnitr Lek; 2014 Feb; 60(2):139-57. PubMed ID: 24754419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease.
    Tedeschi A; Benevolo G; Varettoni M; Battista ML; Zinzani PL; Visco C; Meneghini V; Pioltelli P; Sacchi S; Ricci F; Nichelatti M; Zaja F; Lazzarino M; Vitolo U; Morra E
    Cancer; 2012 Jan; 118(2):434-43. PubMed ID: 21732338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Waldenström macroglobulinemia: my way.
    Gertz M
    Leuk Lymphoma; 2013 Mar; 54(3):464-71. PubMed ID: 22860921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen.
    Treon SP; Hanzis C; Manning RJ; Ioakimidis L; Patterson CJ; Hunter ZR; Sheehy P; Turnbull B
    Br J Haematol; 2011 Aug; 154(3):357-62. PubMed ID: 21615385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.
    Treon SP; Hunter ZR; Matous J; Joyce RM; Mannion B; Advani R; Cook D; Songer J; Hill J; Kaden BR; Sharon D; Steiss R; Leleu X; Branagan AR; Badros A
    Clin Cancer Res; 2007 Jun; 13(11):3320-5. PubMed ID: 17545538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.